Pediatric lymphomatoid papulosis: a broad clinicopathologic spectrum including rare variants in a single-center case series.

Authors

Margherita Pelucchi, Andrea Michelerio, Elif Tamay Gul, Alessandro Svizzero, Elisa Curto, Giuseppe Neri, Marco Paulli, Valeria Brazzelli

Published in

Frontiers in medicine. Volume 13. Pages 1948975. Epub Sep 29, 2026.

Abstract

Lymphomatoid papulosis (LyP) is a rare CD30-positive cutaneous T-cell lymphoproliferative disorder, extremely uncommon in children and adolescents. Despite its indolent course, LyP may mimic malignant lymphomas clinically and histopathologically, making diagnosis challenging in pediatric patients.
To characterize the clinical, histopathologic, immunophenotypic and molecular features of pediatric LyP and to describe treatment approaches and clinical outcomes.
We performed a retrospective observational study of pediatric patients with clinicopathologically confirmed LyP evaluated at our tertiary referral center between 2004 and 2025. Demographic, clinical, histopathologic, immunophenotypic, molecular, treatment and follow-up data were collected.
Nine patients were included (8 males, 1 female), with a median age at diagnosis of 11 years (range 2-18). Lesions predominantly involved the limbs (9/9, 100%), followed by the trunk (5/9, 56%) and hands (4/9, 44%). Ulceration or necrotic evolution occurred in 6/9 patients (67%). Type A was the most common histologic subtype (5/9, 56%), followed by single cases of types B, D, E and one overlap A-C case. CD30 expression was observed in all patients. T-cell receptor clonality was identified in 4/5 tested cases. Management was mainly conservative, consisting of topical corticosteroids and phototherapy (nbUVB or PUVA). Methotrexate was used in one patient. At the last follow-up, all patients were free of active LyP lesions, and no associated hematologic malignancy was documented.
Pediatric LyP shows heterogeneous clinicopathologic features with overall favorable outcomes. However, long-term follow-up remains warranted due to the lifelong risk of associated lymphoproliferative disorders.

PMID:
42871055
Bibliographic data and abstract were imported from PubMed on 14 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.